/
•
•
Detailed stories on technology startups, business and economic current affairs.
The proposed rights issue, at a 90% valuation cut, makes one thing clear: it’s the investors who are calling the shots here.

In February, we wrote that API Holdings, the owner of online drug and medical services startup PharmEasy, might need to sell its diagnostic business Thyrocare to stay afloat. Soon after, the founders said they wouldn’t sell the business. But there were questions about how PharmEasy would pay off the loans it took to buy Thyrocare.
It seems we have the answer now.
This week, PharmEasy announced that it will raise around Rs 2,400 crore through a rights issue to pay off a loan from Goldman Sachs, according to a report in The Economic Times. The company is expected to …